White Matter Hyperintensities and Cerebral Amyloidosis Necessary and Sufficient for Clinical Expression of Alzheimer Disease?

被引:150
作者
Provenzano, Frank A. [1 ,3 ]
Muraskin, Jordan [1 ,3 ]
Tosto, Giuseppe [1 ]
Narkhede, Atul [1 ]
Wasserman, Ben T. [1 ]
Griffith, Erica Y. [1 ]
Guzman, Vanessa A. [1 ]
Meier, Irene B. [1 ]
Zimmerman, Molly E. [4 ]
Brickman, Adam M. [1 ,2 ]
机构
[1] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, Coll Phys & Surg, New York, NY 10032 USA
[2] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
[3] Columbia Univ, Fu Fdn Sch Engn & Appl Sci, New York, NY 10032 USA
[4] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; BRAIN MORPHOLOGY; ELDERLY SUBJECTS; OLDER-ADULTS; RISK-FACTORS; IN-VIVO; BETA;
D O I
10.1001/jamaneurol.2013.1321
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Importance: Current hypothetical models emphasize the importance of beta-amyloid in Alzheimer disease (AD) pathogenesis, although amyloid alone is not sufficient to account for the dementia syndrome. The impact of small-vessel cerebrovascular disease, visualized as white matter hyperintensities (WMHs) on magnetic resonance imaging scans, may be a key factor that contributes independently to AD presentation. Objective: To determine the impact of WMHs and Pittsburgh Compound B (PIB) positron-emission tomography-derived amyloid positivity on the clinical expression of AD. Design: Baseline PIB-positron-emission tomography values were downloaded from the Alzheimer's Disease Neuroimaging Initiative database. Total WMH volume was derived on accompanying structural magnetic resonance imaging data. We examined whether PIB positivity and total WMHs predicted diagnostic classification of patients with AD (n = 20) and control subjects (n = 21). A second analysis determined whether WMHs discriminated between those with and without the clinical diagnosis of AD among those who were classified as PIB positive (n = 28). A third analysis examined whether WMHs, in addition to PIB status, could be used to predict future risk for AD among subjects with mild cognitive impairment (n = 59). Setting: The Alzheimer's Disease Neuroimaging Initiative public database. Participants: The study involved data from 21 normal control subjects, 59 subjects with mild cognitive impairment, and 20 participants with clinically defined AD from the Alzheimer Disease's Neuroimaging Initiative database. Main Outcome Measures: Clinical AD diagnosis and WMH volume. Results: Pittsburgh Compound B positivity and increased total WMH volume independently predicted AD diagnosis. Among PIB-positive subjects, those diagnosed as having AD had greater WMH volume than normal control subjects. Among subjects with mild cognitive impairment, both WMH and PIB status at baseline conferred risk for future diagnosis of AD. Conclusions and Relevance: White matter hyperintensities contribute to the presentation of AD and, in the context of significant amyloid deposition, may provide a second hit necessary for the clinical manifestation of the disease. As risk factors for the development of WMHs are modifiable, these findings suggest intervention and prevention strategies for the clinical syndrome of AD.
引用
收藏
页码:455 / 461
页数:7
相关论文
共 50 条
  • [1] Admiraal-Behloul F., 2004, P INT SOC MAGN RESON, V138
  • [2] Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
    Aizenstein, Howard Jay
    Nebes, Robert D.
    Saxton, Judith A.
    Price, Julie C.
    Mathis, Chester A.
    Tsopelas, Nicholas D.
    Ziolko, Scott K.
    James, Jeffrey A.
    Snitz, Beth E.
    Houck, Patricia R.
    Bi, Wenzhu
    Cohen, Ann D.
    Lopresti, Brian J.
    DeKosky, Steven T.
    Halligan, Edythe M.
    Klunk, William E.
    [J]. ARCHIVES OF NEUROLOGY, 2008, 65 (11) : 1509 - 1517
  • [3] The vascular contribution to Alzheimer's disease
    Altman, Robin
    Rutledge, John C.
    [J]. CLINICAL SCIENCE, 2010, 119 (9-10) : 407 - 421
  • [4] The projected effect of risk factor reduction on Alzheimer's disease prevalence
    Barnes, Deborah E.
    Yaffe, Kristine
    [J]. LANCET NEUROLOGY, 2011, 10 (09) : 819 - 828
  • [5] Neuropathology of older persons without cognitive impairment from two community-based studies
    Bennett, D. A.
    Schneider, J. A.
    Arvanitakis, Z.
    Kelly, J. F.
    Aggarwal, N. T.
    Shah, R. C.
    Wilson, R. S.
    [J]. NEUROLOGY, 2006, 66 (12) : 1837 - 1844
  • [6] β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
    Bourgeat, P.
    Chetelat, G.
    Villemagne, V. L.
    Fripp, J.
    Raniga, P.
    Pike, K.
    Acosta, O.
    Szoeke, C.
    Ourselin, S.
    Ames, D.
    Ellis, K. A.
    Martins, R. N.
    Masters, C. L.
    Rowe, C. C.
    Salvado, O.
    Grp, A. I. B. L. Res
    [J]. NEUROLOGY, 2010, 74 (02) : 121 - 127
  • [7] Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease
    Brickman, Adam M.
    Honig, Lawrence S.
    Scarmeas, Nikolaos
    Tatarina, Oksana
    Sanders, Linda
    Albert, Marilyn S.
    Brandt, Jason
    Blacker, Deborah
    Stern, Yaakov
    [J]. ARCHIVES OF NEUROLOGY, 2008, 65 (09) : 1202 - 1208
  • [8] Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan
    Brickman, Adam M.
    Schupf, Nicole
    Manly, Jennifer J.
    Luchsinger, Jose A.
    Andrews, Howard
    Tang, Ming X.
    Reitz, Christiane
    Small, Scott A.
    Mayeux, Richard
    DeCarli, Charles
    Brown, Truman R.
    [J]. ARCHIVES OF NEUROLOGY, 2008, 65 (08) : 1053 - 1061
  • [9] Long-term Blood Pressure Fluctuation and Cerebrovascular Disease in an Elderly Cohort
    Brickman, Adam M.
    Reitz, Christiane
    Luchsinger, Jose A.
    Manly, Jennifer J.
    Schupf, Nicole
    Muraskin, Jordan
    DeCarli, Charles
    Brown, Truman R.
    Mayeux, Richard
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (05) : 564 - 569
  • [10] Brickman Adam M, 2009, Dialogues Clin Neurosci, V11, P181